Get started
Author

Guowu Wu

Observed names: GUOWU WU, Guo-Wu Wu
ORCID: 0000-0001-6449-4861
Observed ORCID: 0000-0001-6449-4861
OpenAlex ID: A5079300884
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
2024 · Shun Lu, Wei Zhang, et al. · JAMA · 420
Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma
2020 · Lilan Yi, Guowu Wu, et al. · Molecular Therapy — Nucleic Acids · 193
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
2024 · Ying Cheng, Jianhua Chen, et al. · Nature Medicine · 150
PDF
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
2025 · Lin Shen, Yanqiao Zhang, et al. · Nature Medicine · 118
Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer
2020 · Lilan Yi, Ping Huang, et al. · Pharmacological Research · 65
Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study
2023 · Xue Hou, Chengzhi Zhou, et al. · Journal of Thoracic Oncology · 57
PDF
Gefitinib Plus Chemotherapy Versus Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer Patients with Brain Metastases (GAP BRAIN): An Open-Label, Randomized, Multicenter, Phase 3 Study
2022 · Xue Hou, Meichen Li, et al. · JAMA Network Open · 57
PDF
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
2024 · Hua-Qiang Zhou, Ya-Xiong Zhang, et al. · Signal Transduction and Targeted Therapy · 41
PDF
Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis
2020 · Yinfang Gu, Guowu Wu, et al. · Medical Science Monitor · 22
PDF
KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
2023 · Juanzi Zeng, Wenwei Fan, et al. · International Journal of General Medicine · 21
PDF
Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R
2023 · Siming Liu, Chuan Huang, et al. · Journal of Enzyme Inhibition and Medicinal Chemistry · 11
PDF
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
2025 · Hua-Jun Chen, Hai-Yan Tu, et al. · Journal of Hematology & Oncology · 9
PDF
A Novel and Highly Selective Epidermal Growth Factor Receptor Inhibitor, SMUZ106, for the Treatment of Glioblastoma
2023 · Ying Jiang, Chunhui Huang, et al. · Pharmaceutics · 6
PDF
A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors.
2025 · Jie Wang, Rui Wan, et al. · Journal of Clinical Oncology · 5
PDF
Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review
2024 · Yinfang Gu, Lilan Yi, et al. · Frontiers in Oncology · 5
Bioinformatics Analysis and Screening of Potential Target Genes Related to the Lung Cancer Prognosis
2023 · Ping Huang, Yinfang Gu, et al. · Medical Principles and Practice · 5
Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy
2020 · Xiaofang Zou, Longhua Guo, et al. · Journal of Cancer · 4
PDF
First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China
2025 · Xue Hou, Chengzhi Zhou, et al. · EClinicalMedicine · 3
Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial
2025 · Yuqin Song, Qingqing Cai, et al. · Blood · 3
PDF
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors
2024 · Chenfei Zhou, Jinling Jiang, et al. · Experimental Hematology and Oncology · 3
PDF
PRMT5-PAK1 Signaling Participates in Metastasis and Is Associated With Poor Prognosis in Human Esophageal Carcinoma
2024 · XIAOFANG ZOU, YIWEN LIN, et al. · Anticancer Research · 3
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
2021 · Li Zhang, Wenfeng Fang, et al. · Journal of Clinical Oncology · 3
Discovery of 3-phenyl-[1,2,4]triazolo[4,3-a]pyridine derivatives as potent smoothened inhibitors against colorectal carcinoma
2025 · Fengqiu Guo, Yangcheng Ai, et al. · Bioorganic & Medicinal Chemistry · 2
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
2025 · Lin Shen, Yanqiao Zhang, et al. · Nature Medicine · 2
PDF
Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma
2024 · Guowu Wu, Mingfeng Zhou, et al. · Bioorganic Chemistry · 2
Works count: 46
Citation count: 1,221
H-index: 11
I10-index: 11
Year
Topic
Type